Verona Pharma plc Stock News

LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirat

LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato

Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel COPD treatment, ensifentrine, exhibiting promise in addressing significant unmet needs in the COPD market. T

LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview

Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in COPD. Phase 3 data showed that the drug showed a 40% pooled reduction in the rate of e

Verona Pharma plc (NASDAQ:VRNA ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Offi

12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4

LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirat

Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air

The Nasdaq 100 is on a tear

Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trial

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c

Verona Pharma's ensifentrine achieved positive results in a Phase 3 study with an indication for COPD. Ensifentrine is also in Phase 2 studies to address asthma and cystic fibrosis.

Verona Pharma plc (NASDAQ:VRNA ) Q4 2022 Earnings Conference Call March 7, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Of

LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato